NCT07225621 2026-03-19
Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
Alpheus Medical, Inc.
Phase 2 Recruiting
Clinical Trials
35 trialsNCT06665724 2026-02-27
Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With Newly Diagnosed High-Grade Glioma (HGG) Prior to Resection and Standard Adjuvant Therapy (ALA SDT GLIOMA 401)
Universität Münster
Phase 1 Completed
NCT07076472 2026-02-23
Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of Progressive or Recurrent Glioblastoma
Mayo Clinic
Phase EARLY_PHASE1 Recruiting
NCT06907485 2026-01-21
A Multicenter Study to Assess the Feasibility of 5-Aminolevulinic Acid (5-ALA) in Pediatric Brain Tumor Patients
University of Pittsburgh
Phase 2 Not yet recruiting
NCT04738162 2025-12-10
Clinical Safety Study on 5-Aminolevulinic Acid (5-ALA) in Children and Adolescents With Brain Tumors
Universität Münster
Phase 2 Completed
NCT02191488 2025-09-15
ALA-induced PpIX Fluorescence During Brain Tumor Resection
Dartmouth-Hitchcock Medical Center
Phase 1 Active not recruiting
NCT05736406 2025-09-11
A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma
Hemerion Therapeutics
Phase 1/2 Recruiting
NCT02691923 2025-08-03
Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker
Dartmouth-Hitchcock Medical Center
Phase 2 Recruiting
NCT05362409 2025-06-19
Study to Evaluate 5-ALA Combined With CV01 Delivery of Ultrasound in Recurrent High Grade Glioma
Alpheus Medical, Inc.
Phase 1 Completed
NCT03897491 2025-05-14
PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma
photonamic GmbH & Co. KG
Phase 2 Active not recruiting
NCT02728388 2025-05-08
Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II
Medical College of Wisconsin
Phase 2 Recruiting
NCT04469699 2025-03-11
NOA11
University Hospital Muenster
Phase 2 Terminated
NCT05590689 2024-12-16
ALA-RDTinGBM
Universität Münster
Phase 1/2 Recruiting
NCT04305470 2024-06-18
MEN-301
NX Development Corp
Phase 3 Completed
NCT01128218 2023-11-30
A Study of the Specificity and Sensitivity of 5- Aminolevulinic Acid (ALA) Fluorescence in Malignant Brain Tumors
Southern Illinois University
Phase 1/2 Completed
NCT01502280 2023-11-24
BALANCE
St. Joseph's Hospital and Medical Center, Phoenix
Phase 3 Completed
NCT05850377 2023-05-09
5-Aminolevulinic Acid (5-ALA) Gliolan®: Usage Increase Proposal for Neurosurgical Procedures in High-Grade Gliomas
Sociedad de Lucha Contra el Cáncer del Ecuador
Not yet recruiting
NCT04055688 2022-05-31
Novel Exoscope System for 5-ALA Fluorescence-Guided Surgery for Gliomas
H. Lee Moffitt Cancer Center and Research Institute
Completed
NCT02155452 2022-05-06
ALAglioma
Tata Memorial Hospital
Completed
NCT00752323 2021-09-17
Imaging Procedure Using ALA in Finding Residual Tumor in Grade IV Malignant Astrocytoma
Case Comprehensive Cancer Center
Phase 2 Completed
NCT01682811 2021-06-18
Phase I Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1)
Medical College of Wisconsin
Phase 1 Completed
NCT00977795 2019-09-10
A Study of the Specificity and Sensitivity of 5-ALA Fluorescence in Malignant Brain Tumors
Endeavor Health
Phase 1/2 Withdrawn
NCT00870779 2019-06-14
FGR
Dartmouth-Hitchcock Medical Center
Phase 1 Completed
NCT00961090 2019-04-12
Safety Study of Aminolevulinic Acid (ALA) to Improve Visibility of Brain Tumors During Surgery
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Phase 2 Completed
NCT01575275 2018-07-31
Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT01310868 2017-10-05
Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma
University College, London
Phase 2 Completed
NCT01148966 2017-02-15
Aminolevulinic Acid During Surgery in Treating Patients With Malignant Brain Tumors
University of Washington
Phase 1 Terminated
NCT02119338 2017-01-06
5-ALA in Recurrent Glioma
St. Joseph's Hospital and Medical Center, Phoenix
Phase NA Unknown
NCT01502605 2017-01-05
Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Terminated
NCT02755142 2016-05-23
Clinical Study on 5-aminolevulinic Acid Hydrochloride (5-ALA) for Fluorescence-guided Resection of Malignant Gliomas
medac GmbH
Phase 1/2 Completed
NCT01445691 2016-05-17
More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery
Icahn School of Medicine at Mount Sinai
Phase 2 Withdrawn
NCT01351519 2016-03-17
A Study of Aminolevulinic Acid Used to Enhance Visualization and Surgical Removal of Brain Tumors
MultiCare Health System Research Institute
Phase 2 Terminated
NCT01798771 2013-02-26
IMAGER
Johann Wolfgang Goethe University Hospital
Phase NA Unknown
NCT00241670 2012-04-26
Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid
medac GmbH
Phase 3 Completed
NCT00671710 2011-01-14
Study of Aminolevulinic Acid to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain
Advocate Hospital System
Phase 1 Completed